Biosimilars Market Forecast 2035:
According to the report, the biosimilars market is anticipated to grow from USD 31.6 Billion in 2024 to USD 125.9 Billion in 2035 at a CAGR of 13.4% during the forecast period. The biosimilars market continues to expand rapidly, as more individuals seek lower-cost and more efficient treatment options. Biosimilars are nearly identical replicas of ultra-expensive biologic medicines used to treat serious diseases, including cancer, arthritis and diabetes. As more patients and healthcare providers learn about biosimilars and their safety and efficacy, they are being accepted and used increasingly around the world.
In 2024, several new biosimilars were introduced into the United States, Europe and Asia, for both hospital-use and home-care. Businesses are also rolling out smart delivery systems (like injection pens that connect to your smart phone app), allowing patients to monitor doses, be notified to comply with reminders and report adverse events. These tools improve accessibility to biosimilar treatment, offer tailored adherence plans and generally provide higher patient confidence.
Governments and health authorities are also moving to refresh their biosimilar policies and share more information about the safety and effectiveness of biosimilars, with intent to build confidence. The acceptance of biosimilars into medical guidelines and educational programming will continue to fuel usage.
Our society yearns for not just affordable treatment options, but smarter treatments that offer a more tailored approach. Biosimilars, with clear and obvious advantages in affordability, projected systems offering more digital support, are continuing to contribute to sustained, modern and accessible healthcare.
Some of the market leaders in the biosimilars market include Biocon Biologics; Amgen; Sandoz (Novartis division); Pfizer; and Samsung Bioepis. All these players are putting a huge amount of money in research, development and manufacturing to create a wide-ranging, compliant portfolio of high-quality biosimilar drugs for markets across the globe. In addition, a number of large pharma players and biotechs are establishing mini-partnerships that can speed innovation and market entry.
The biosimilar market is full of promise, but there are also several challenges that biosimilar drugs face. There are complex and long regulatory pathways, as well as long clinical trials to prove safety and efficacy. Pioneer biologic developers create hurdles through patent extension and other market tactics, which can give competitors delay in entering the market. Adoption may also be deterred in certain markets by professional and patient reticence about biosimilars themselves, or ignorance, or confidence in such products.
There still exists a bright future for biosimilars. More and more of the biologic drug patents will keep expiring, and new biosimilar average sales prices (ASP) will surface and compete in the marketplace. With the need for quality affordable treatment continuing to grow, and with the focus for increased cost coverage of treatments for chronic illnesses like cancer and autoimmune diseases, the market for biosimilars is expanding very fast. Governments and other health care providers are also increasingly advocating biosimilars as a first choice in treatment in an attempt to reduce health care spending. Advances in technology, enhanced understanding, and cross-border cooperation are affirming a shift toward accelerated approval procedures and higher acceptance rates by patients and healthcare professionals, leading to a gradual expansion of biosimilars into the future.
The Influence of Global Tariff Regulations on the Growth and Strategies of the Biosimilars Industry
Tariff regulations—taxes imposed on imported or exported products—have a very real effect on the biosimilars industry. High tariffs imposed by countries on biosimilar imports drive up costs to companies wanting to enter new markets, making these medicines less affordable and furthering slowing global access to these medicines.
Further it also may cause manufacturers to avoid exporting to these regions altogether or require manufacturers to establish local production, which has costs associated. Comparatively, countries that have low tariffs or small tariffs (or none) encourage cross-border commerce of biosimilars, which stimulates more widespread access to these medicines. As a result, manufacturers have adapted by identifying ways of guaranteeing local manufacturing, establishing local partnerships, and developing flexible supply chains to circumvent trade barriers and maintain growth.
Key players operating in the biosimilars market include Accord Healthcare Ltd., Alvotech, Amgen Inc., Apotex Inc., Biocon Biologics Ltd., Boehringer Ingelheim, Celltrion Inc., Coherus BioSciences, Dr. Reddy’s Laboratories, Eli Lilly and Company, Fresenius Kabi, Intas Pharmaceuticals Ltd., Kashiv BioSciences LLC, Merck KGaA, Mylan N.V. (now part of Viatris), Nichi-Iko Pharmaceutical Co., Ltd., Novartis AG (Sandoz), Pfizer Inc., Reliance Life Sciences, Roche Holding AG, Samsung Bioepis, Sanofi S.A., Shanghai Henlius Biotech, Inc., STADA Arzneimittel AG, Teva Pharmaceutical Industries Ltd., Xbrane Biopharma AB, and Other Key Players.
MarketGenics is a global market research and management consulting company empowering decision makers from startups, Fortune 500 companies, non-profit organizations, universities and government institutions. Our main goal is to assist and partner organizations to make lasting strategic improvements and realize growth targets. Our industry research reports are designed to provide granular quantitative information, combined with key industry insights, aimed at assisting sustainable organizational development.
We serve clients on every aspect of strategy, including product development, application modeling, exploring new markets and tapping into niche growth opportunities.
800 N King Street Suite 304 #4208 Wilmington, DE 19801 United States.
+1(302)303-2617
info@marketgenics.co
3rd floor, Indeco Equinox, Baner Road, Baner, Pune, Maharashtra 411045 India.
sales@marketgenics.co
Table of Contents
Note* - This is just tentative list of players. While providing the report, we will cover more number of players based on their revenue and share for each geography
We will customise the research for you, in case the report listed above does not meet your requirements.
Get 10% Free Customisation